A phase I open label safety and pharmacokinetic study of Navitoclax (ABT-263) in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors

Trial Profile

A phase I open label safety and pharmacokinetic study of Navitoclax (ABT-263) in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2015

At a glance

  • Drugs Navitoclax (Primary) ; Carboplatin; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 26 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top